Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) HAS THE CURRENT QUARTER GROWTH OF 18.8%
A number of analysts rated the stock as well: 3 analysts believe that the stock is a STRONG BUY while 3 reported it as Buy.0 analysts assigned a HOLD rating, 0 said it’s UNDERPERFORM and 0 say that this stock is a SELL
5 number of analysts also provided their insight on Aurinia Pharmaceuticals Inc, where the Average Price Target for the stock is $7.8. They also projected Low Price Target as $6 while High Price Target
http://newburghpress.com/2016/08/16/aurinia-pharmaceuticals-inc-nasdaqauph-has-the-current-quarter-growth-of-18-8/
Analysts’ Updated EPS Estimates for August, 16th (AET, AUPH, BLT, BRS, BTLCY, CDTX, CLSN, DVN, EME, EV)
http://sleekmoney.com/analysts-updated-eps-estimates-for-august-16th-aet-auph-blt-brs-btlcy-cdtx-clsn-dvn-eme-ev/1467417/
Healthcare - Top 5 Gainers / Losers as of 11:00 am
http://seekingalpha.com/news/3203728-healthcare-top-5-gainers-losers-11-00
Aurinia Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $7.15.
http://www.americanbankingnews.com/2016/08/16/aurinia-pharmaceuticals-inc-auph-rating-reiterated-by-leerink-swann/
Tuesday’s Top Health Care Movers
http://247wallst.com/healthcare-business/2016/08/16/tuesdays-top-health-care-movers/
Biotech Considerable Stocks on Returns- Aurinia Pharmaceuticals
http://www.senecaglobe.com/biotech-considerable-stocks-on-returns-aurinia-pharmaceuticals-nasdaqauph-heat-biologics-nasdaqhtbx/335231/
Biotechnology Stocks That Must Be on Your Watch List: Aurinia Pharmaceuticals Inc
http://postregistrar.com/2016/08/16/biotechnology-stocks-that-must-be-on-your-watch-list-aurinia-pharmaceuticals-inc-nasdaqauph-eleven-biotherapeutics-inc-nasdaqebio/
5 Analysts reported that the Price Target for Aurinia Pharmaceuticals Inc might touch $10 high while the Average Price Target and Low price Target is $7.8 and $6 respectively.
http://www.newsoracle.com/2016/08/16/comprehensive-analysis-of-aurinia-pharmaceuticals-inc-nasdaqauph/
Analysts Watching Stocks: Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)
http://www.streetupdates.com/2016/08/16/analysts-watching-stocks-aurinia-pharmaceuticals-inc-nasdaqauph-zimmer-biomet-holdings-inc-nysezbh/
FBR & Co restated their outperform rating on shares ofAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) in a research note released on Monday
http://www.mideasttime.com/aurinia-pharmaceuticals-inc-auph-receives-outperform-rating-from-fbr-co/1197174/
Stock In Momentum Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has received a high momentum style score by Zacks. The score is arrived, taking into account some aspects, which signal that the stock has attained a favourable position after its movement in either upward or downward direction.
http://theenterpriseleader.com/analyst-research/stock-in-momentum-aurinia-pharmaceuticals-inc-nasdaqauph-7/142228/
WILL AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) HIT $9 PRICE TARGET
http://www.investornewswire.com/analyst-views/will-aurinia-pharmaceuticals-inc-nasdaqauph-hit-9-price-target/150333/
Patient deaths distract the Street from Aurinia promising lupus data
What should have been a big win for Aurinia Pharmaceuticals Inc.’s stock (NASDAQ:AUPH) Monday on the back of positive phase IIb data in the particularly tough lupus nephritis (LN) indication turned into a drubbing for the shares, which plunged 56 percent as investor attention focused – perhaps unfairly – on the study’s death rate.
http://www.bioworld.com/content/patient-deaths-distract-street-aurinia-pharmaceuticals-promising-lupus-data
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy recommendation.
http://www.mideasttime.com/zacks-aurinia-pharmaceuticals-inc-nasdaqauph-given-average-rating-of-strong-buy-by-analysts/1191978/
Based on the results of the 24-week analysis, Aurinia plans to meet with the U.S. Food and Drug Administration in the fourth quarter of 2016 to discuss these data and the drug’s subsequent clinical development and path to registration in LN.
http://www.pharmavoice.com/newsreleases/aurinia-pharmaceuticals-announces-voclosporin-meets-primary-endpoint-phase-iib-aura-lv-study-lupus-nephritis/
most of the death occured in asian countries where health regulation is not as stringent as usa. the end stage of this disease is very similar end stage cancer disease, where patient goes to palliatve care. these patient were in death bed, and died mostly on infection which the secondary condition of the disease. admiinistration of the drug did not contribute the death of these patients.
The reported results were positive, and represent the first time an LN therapy has hit a primary endpoint in a global clinical study for this particular type of the disease. Despite optimistic trial data, investors have more than halved the biotech developer’s market value.
http://www.economiccalendar.com/2016/08/15/aurinia-pharmaceuticals-auph-plunges-despite-upbeat-trial-data/
The results of this trial are welcomed and exciting news for people with lupus and their doctors who are eager to have more tolerable and effective treatment options.
http://www.marketwired.com/press-release/lupus-foundation-america-statement-on-successful-results-phase-iib-clinical-trial-voclosporin-2150698.htm
Lupus Foundation of America Statement on Successful Results of Phase IIB Clinical Trial of Voclosporin
http://www.marketwired.com/press-release/lupus-foundation-america-statement-on-successful-results-phase-iib-clinical-trial-voclosporin-2150698.htm
“While this does naturally raise questions, it is important to be mindful that these lupus nephritis patients were extremely sick and treated at many sites with differing practice patterns in Asia, some of which we believe were in much less developed places,” Leerink said in a note to clients.
http://www.fiercebiotech.com/biotech/aurinia-pharmaceuticals-lupus-candidate-aces-phii-prepares-for-fda-talks
The company said however that these deaths were due to the severe underlying nature of the disease, and not its drug.
http://www.fiercebiotech.com/biotech/aurinia-pharmaceuticals-lupus-candidate-aces-phii-prepares-for-fda-talks
Leerink Partners Reiterates 'Outperform' on Aurinia Pharmaceuticals (AUPH) Following Phase 2b AURA-LV Results
http://www.streetinsider.com/Analyst+Comments/Leerink+Partners+Reiterates+Outperform+on+Aurinia+Pharmaceuticals+(AUPH)+Following+Phase+2b+AURA-LV+Results/11938729.html
U.S. Antimony Reports Antimony Price Increase and Large Zeolite Order - 5/2/2016 8:00:00 AM ET
THOMPSON FALLS, Mont.--(BUSINESS WIRE)--United States Antimony Corporation (“USAC”, NYSE MKT “UAMY”) reported the following sales for April: Product April 2016 Antimony pounds 221,145 BRZ zeolite tons 1,253 Gold from...
http://www.metalsnews.com/news_archive.aspx?SearchText=UAMY
U.S. Antimony Reports Production
http://www.marketwatch.com/story/us-antimony-reports-production-2016-08-01-81593821
someone has placed and order to buy 40000 @1,75. means he has to cover for his short. if no one sell he has to buy in higher price 2
Alimera Sciences announces clinical presentations and sponsored Symposia at ASRS 2016 Annual meeting,
https://finance.yahoo.com/news/alimera-sciences-announces-clinical-presentations-113000845.html
Diabetic Macular Edema Patients Gain Or Maintain Vision With Iluvien® At 12 Month
http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=168411#.V6lS89QrLMo
Alimera Sciences, Inc.’s Return on Investment stands at 395.20% . Alimera Sciences, Inc.’s Return on Equity (ROE) is 77.40%. http://presstelegraph.com/2016/08/08/trading-recap-zooming-in-on-shares-of-alimera-sciences-inc-nasdaqalim/
State Street Corp increased its position in Alimera Sciences Inc. (NASDAQ:ALIM) by 15.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission.
http://baseballnewssource.com/markets/alimera-sciences-alim-market-perform-rating-reaffirmed-at-cowen-and-company/60190/
Alimera Sciences’ (ALIM) “Market Perform” Rating Reaffirmed at Cowen and Company.
http://baseballnewssource.com/markets/alimera-sciences-alim-market-perform-rating-reaffirmed-at-cowen-and-company/60190/
total number of share shorted 1,259,500 and days to cover this short is 6.9 days. this number is unusually high for a biopharmasuitical with high potential. shots are feeling the pain. this stock will go beyond 2.10 at the end of the day. hold on to that. do not sell.
What Analysts Say about ALIM. The Company has received rating from WSJ analysts. 3 Months Ago, the stock has been rated as “Buy” from 2 Analysts, The stock has received “BUY” rating after consensus analysis from analysts.
In the liquidity ratio analysis; Alimera Sciences, Inc.’s (ALIM) current ratio was 0.90. The company has the institutional ownership of 88.90% while the Beta factor was 2.25. The stock’s RSI amounts to 57.17.
http://www.streetupdates.com/2016/08/05/stocks-inside-analysts-spotlight-alimera-sciences-inc-nasdaqalim-merrimack-pharmaceuticals-inc-nasdaqmack/
Increased Volatility Sighted on Shares of Alimera Sciences, Inc. (NASDAQ:ALIM)
Recommendation
Based on the current consensus analyst target Price of 7.50, analysts have a current recommendation of 2.30 on the shares. This is on a consensus basis according to Thomson Reuters. Using the formula PEG (P/E) / Annual EPS Growth (the ratio used to determine a stock’s value while taking into account the earnings’ growth), Wall Street is confident with this recommendation.
http://www.engelwooddaily.com/increased-volatility-sighted-on-shares-of-alimera-sciences-inc-nasdaqalim/568993/
two analyst upgraded to hold and one buy.
http://www.thefoundersdaily.com/analyst-rating-update-on-alimera-sciences-alim/634608/
[img][/img]
Date Open High Low Close Volume Adj
Close
2016/08/03 2.07 2.09 1.90 2.00 918,682 2.00
2016/08/02 2.08 2.0811 1.96 2.02 664,184 2.02
2016/08/01 2.06 2.24 1.90 2.08 1,669,284 2.08
2016/07/29 2.00 2.12 1.85 2.04 3,181,048 2.04
2016/07/28 1.61 2.10 1.57 2.07 5,633,272 2.07
past few days history without major news.
if you check level 2, you will see there are not too many seller. only 100 or 200 or 300. they are deliberately trying to depress the price. Since too many share are bought at early, people are waiting at the end of the day or eary tomorrow to buy again.
Optometrists Correctly Identify nAMD Needing Retreatment
The National Institute for Health Research Health Technology Assessment Programme funded this study. Five coauthors reported various financial disclosures, involving National Institute for Health Research, Alimera Sciences, Bayer, Roche, Novartis, and/or Allergan. The other authors have disclosed no relevant financial relationships
http://www.medscape.com/viewarticle/867082
Metabolix is winding down biopolymers operations
Metabolix, Inc. has announced that it is implementing a strategic restructuring under which Yield10 Bioscience will become its core business. The focus will be on developing disruptive technologies for step-change improvements in crop yield to enhance global food security.
As part of the restructuring, Metabolix will eliminate approximately 45 positions in its biopolymer operations and corporate organization, and will pursue the sale of its biopolymers business assets. The immediate reduction in force represents approximately 50% of the Company's current workforce. Once the restructuring is complete, Metabolix anticipates a staff of approximately 20 people, comprised of the Yield10 crop science team together with a small group of administrative personnel. [u]After the restructuring and wind-down of the biopolymers operation, the Company's annual cash burn rate is expected to be in the range of $5 million compared to approximately $25 million prior to the restructuring.[color=red][/color] Consistent with its new strategy, the Company plans to rebrand itself as Yield10 Bioscience in the coming months.
http://www.bioplasticsmagazine.com/en/news/meldungen/20160725-Metabolix-winds-up-biopolymers-operations.php
$MBLX out of total volume 23048, only 300 share sold to below .58. to cover the short 80.9 days needed highest of any.
http://ih.advfn.com/stock-market/NASDAQ/mannkind-corp-mm-MNKD/level2
the number of share shorted 833,700 and days to cover the shortage is 80.9 days this is the highest in recent means tomorrow will sky rocketing.
http://shortsqueeze.com/data.php?symbol=mblx&submit=Short+Quote%99